Under the terms of the definitive agreement, AstraZeneca will acquire all of Gracell's fully diluted share capital (including shares represented by ADSs) through a merger for a price of $2.00 per ordinary
Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
U.S. stocks traded mixed, with the Dow Jones gaining around 90 points on Friday.
Shares of Bitfarms Ltd. (NASDAQ: BITF) shares fell sharply during Friday’s session after the company announced a C$60 million private placement with U.S. institutional investors.